coronary artery disease
Conditions
Interventions
salvianolate group:salvianolate injection
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age=18 years; 2. Clinical diagnosed non-ST segment elevated acute coronary syndrome or stable angina pectoris, who are planned to undergo selective coronary angiography or intervention; 3. Written informed consent
Exclusion criteria
Exclusion criteria: 1. ST segment elevated acute coronary syndrome or high risk non-ST segment elevated acute coronary syndromestable angina pectoris, who are planned to undergo urgent coronary angiography or intervention; 2. Renal dialysis; 3. Intravenous or intra-artery administration of iodinated contrast media less than 7 days prior to study drug/comparator drug injection; 4. Nephrotoxic medications administration less than 24 hours prior to study drug/comparator drug injection, including diuretics, biguanides, NSAID, aminoglycosides, et al.; 5. Severely-impaired left ventricular function (ejection fraction <30%) or end-stage congestive heart failure; 6. Cardiac shock; 7. Allergy to salvianolate; 8. Have or are suspected of pregnant or nursing; 9. Previously participated in this study; 10. Participation in any investigational drug study less than 30 days prior to enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of myocardial injury post coronary artery intervention;the incidence of contrast induced nephropathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| nterleukin-18,IL-18;neutrophil gelatinase-associated lipocalin,NGAL;kidney injury molecule-1,KIM-1;liver-type fatty acid-binding protein,L-FABP; | — |
Countries
China
Contacts
Public ContactGao Wei
Outcome results
None listed